Protective effect of creatine on amikacin-induced ototoxicity

Apaydın, Emre; Dağlı, Elif; Bayrak, Sevinç; Kankılıç, Ekrem Said; Hasan, Sahin; Acar, Aydın

doi:10.1016/j.bjorl.2020.09.002

Cited by 2 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar finding was observed with the clinically modified or adopted responder criteria (American Speech-Language-Hearing Association, 1994). This finding was comparable to the effect of ebselen on amikacin treated mice (Longenecker et al, 2020), and provides evidence that ebselen or other otoprotective drugs might work at ameliorating AG-induced hearing loss in clinic (Avci et al, 2016;Fox et al, 2016;Dogan et al, 2017;El-Anwar et al, 2018;Apaydin et al, 2021). However, the threshold shifts seen here were drastically different than those found with a similar tobramycin dosing experiment in Swiss-Webster mice (Gu et al, 2020).…”

Section: Tobramycin-induced Temporary Threshold Shifts Can Occur Without Permanent Cochlear Damagesupporting

confidence: 74%

Development of Tinnitus and Hyperacusis in a Mouse Model of Tobramycin Cochleotoxicity

Longenecker¹,

Gu²,

Homan³

et al. 2021

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Aminoglycosides (AG) antibiotics are a common treatment for recurrent infections in cystic fibrosis (CF) patients. AGs are highly ototoxic, resulting in a range of auditory dysfunctions. It was recently shown that the acoustic startle reflex (ASR) can assess behavioral evidence of hyperacusis and tinnitus in an amikacin cochleotoxicity mouse model. The goal of this study was to establish if tobramycin treatment led to similar changes in ASR behavior and to establish whether ebselen can prevent the development of these maladaptive neuroplastic symptoms. CBA/Ca mice were divided into three groups: Group 1 served as a control and did not receive tobramycin or ebselen, Group 2 received tobramycin (200 mg/kg/s.c.) and the vehicle (DMSO/saline/i.p.) daily for 14 continuous days, and Group 3 received the same dose/schedule of tobramycin as Group 2 and ebselen at (20 mg/kg/i.p.). Auditory brainstem response (ABR) and ASR hearing assessments were collected at baseline and 2, 6, 10, 14, and 18 weeks from the start of treatment. ASR tests included input/output (I/O) functions which assess general hearing and hyperacusis, and Gap-induced prepulse inhibition of the acoustic startle (GPIAS) to assess tinnitus. At 18 weeks, histologic analysis showed predominantly normal appearing hair cells and spiral ganglion neuron (SGN) synapses. Following 14 days of tobramycin injections, 16 kHz thresholds increased from baseline and fluctuated over the 18-week recovery period. I/O functions revealed exaggerated startle response magnitudes in 50% of mice over the same period. Gap detection deficits, representing behavioral evidence of tinnitus, were observed in a smaller subset (36%) of animals. Interestingly, increases in ABR wave III/wave I amplitude ratios were observed. These tobramycin data corroborate previous findings that AGs can result in hearing dysfunctions. We show that a 14-day course of tobramycin treatment can cause similar levels of hearing loss and tinnitus, when compared to a 14-day course of amikacin, but less hyperacusis. Evidence suggests that tinnitus and hyperacusis might be common side effects of AG antibiotics.

show abstract

Section: Tobramycin-induced Temporary Threshold Shifts Can Occur Without Permanent Cochlear Damagesupporting

confidence: 74%

Development of Tinnitus and Hyperacusis in a Mouse Model of Tobramycin Cochleotoxicity

Longenecker¹,

Gu²,

Homan³

et al. 2021

Front. Mol. Neurosci.

View full text Add to dashboard Cite

show abstract

Otoprotective effects of farnesene against oxidative damage induced by paclitaxel

Dinçer

Atalay

Tatar

2022

Cukurova Medical Journal

View full text Add to dashboard Cite

Amaç: Bu çalışmanın amacı, güçlü serbest radikal süpürücü ve antioksidan özelliklere sahip farnesenin paklitaksel kaynaklı ototoksisite üzerindeki etkilerini biyokimyasal ve fonksiyonel yönden araştırmaktır. Gereç ve Yöntem: On sekiz erkek Wistar albino sıçan, altı sıçandan oluşan üç gruba rastgele ayrıldı. Araştırma boyunca kontrol grubuna paklitaksel veya farnesen verilmedi. Paklitaksel grubuna, 5mg/kg paklitaksel intraperitoneal olarak dört kez (1., 7., 14. ve 21. günlerde) verildi. Farnesen + paklitaksel grubuna, önce 5 mg/kg paklitaksel, 30 dakika sonra 50 mg/kg farnesen intraperitoneal olarak 4 kez (1., 7., 14. ve 21. günlerde) verildi. 0. ve 21. günlerde tüm sıçanların otoakustik emisyon ölçümü yapıldı. Daha sonra hayvanlar sakrifiye edildi ve biyokimyasal testler için kokleaları çıkarıldı. Bulgular: Paklitaksel, önemli ölçüde malondialdehit seviyelerini yükselterek ve glutatyon seviyelerini düşürerek kokleada oksidatif strese neden oldu. Ayrıca paklitaksel grubunun distorsiyon ürünü otoakustik emisyon değerleri diğer gruplara göre anlamlı derecede düşüktü. Farnesen+paklitaksel grubunda ise paklitakselin çeşitli biyokimyasal ve fonksiyonel parametrelerde oluşturduğu hasarda iyileşmeler gözlendi. Sonuç: Çalışma sonuçları doğal bir antioksidan olan farnesen’in sıçanlarda paklitaksel kaynaklı işitme kaybını azalttığını, farnesen ve paklitaksel kombinasyonunun gelecekte klinik kullanım için paklitaksel kaynaklı ototoksisiteden koruyabileceğini göstermektedir.

show abstract

Protective effect of creatine on amikacin-induced ototoxicity

Cited by 2 publications

References 32 publications

Development of Tinnitus and Hyperacusis in a Mouse Model of Tobramycin Cochleotoxicity

Development of Tinnitus and Hyperacusis in a Mouse Model of Tobramycin Cochleotoxicity

Otoprotective effects of farnesene against oxidative damage induced by paclitaxel

Contact Info

Product

Resources

About